Updates and challenges on treatment with BRAF/MEK-inhibitors in melanoma.

ABSTRACT:

Introduction

Breakthroughs in targeted therapy have significantly improved outcomes for many patients with advanced melanoma, including those with BRAFV600 mutant disease. Targeted therapy for BRAFV600-mutant metastatic melanoma includes combinations of BRAF inhibitors and MEK inhibitors, which improve response rates and prolong progression-free survival (PFS) and overall survival (OS) in these patients. However, while durable responses have been observed, many patients develop acquired resistance to these drugs.

Areas covered

Recent clinical trial updates and ongoing studies with targeted therapy for BRAF-V600 mutant melanoma are reviewed.

Expert opinion

Although BRAF targeted therapy remains an effective treatment for BRAF-mutant for melanoma, ongoing trials are exp

SUBMITTER: Eroglu Z 

PROVIDER: S-EPMC6296476 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature